Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

However, as it progresses, it can cause symptoms such as itchy skin, pruritus, and a rash. Around 35.5 million adults in the United States live with kidney disease, but only about 10% know they ...

Skin biopsy: To do this, your dermatologist removes a small sample from your rash, so that it can be examined under a microscope. Nail biopsy: If lichen planus may be affecting one or more of your ...

Rash during pregnancy is not uncommon, ranging from a relatively harmless heat rash to potentially life-threatening conditions like impetigo herpetiformis. These rashes may develop due to changes in ...

A rash is a generic term for an area of irritated skin. This irritation can take many forms, including redness, swelling, itching, and dryness. This is a rash that was once a hallmark sign of Graves' ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

Shaving with a razor is a quick, cheap and efficient way of banishing unwanted hair, but it occasionally comes with an unwanted side effect: shaving rash, or as it's more commonly known razor burn.

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...